Physician profile
Ee Lin Wan
NPI 1558532317
$2,514.81
in general payments reported to CMS, 2019-2025
18 companies · $880 in 2025
The $880 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $443 · 2023: $538 · 2024: $655 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $734.91 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $557.68 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $271.17 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $187.37 | 2023-2024 | Creon, Linzess, Viberzi |
| Otsuka America Pharmaceutical, INC. | $148.20 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $135.77 | 2022-2025 | |
| Inspire Medical Systems, INC. | $116.21 | 2024-2025 | Inspire |
| Corcept Therapeutics | $67.29 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $58.94 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $45.28 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Rhythm Pharmaceuticals, INC. | $40.36 | 2023 | Imcivree |
| Madrigal Pharmaceuticals | $28.91 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $28.49 | 2025 | Watchman Access System |
| Sumitomo Pharma America, INC. | $20.96 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $20.75 | 2025 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.43 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.38 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $14.71 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ee Wan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.